Monoclonal antibody therapy of ovarian cancer

References

• Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Clin.54, 8–29 (2004).
   PubMed Web of Science ®Google Scholar
• Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin. Oncol.29, 105–112 (2002).
   PubMed Web of Science ®Google Scholar
• Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with Campath-1H in patients with relapsed high-and low-grade non-Hodgkin’ lymphomas: a multicenter Phase I/II study. Ann. Hematol.81, 26–32 (2002).
   PubMed Web of Science ®Google Scholar
• Yip YL, Ward R. AntiErbB-2 monoclonal antibodies and ErbB-2 directed vaccines. Cancer Immunol. Immunother.50, 569–587 (2002).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22, 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21, 60–65 (2003).
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, Di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med.10, 145–147 (2004).
   PubMed Web of Science ®Google Scholar
• Schultes BC, Nicodemus CF. Using antibodies in tumour immunotherapy. Expert Opin. Biol. Ther.4, 1265–1284 (2004).
   PubMed Web of Science ®Google Scholar
• Berek JS. Epithelial ovarian cancer. In: Practical Gynecologic Oncology, 4th edition. Berek JS, Hacker NF (Eds), Lippincott Williams & Wilkins, PA, USA, 443–509 (2005).
   Google Scholar
• Du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst.95, 1320–1329 (2003).
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol.21, 3194–3200 (2003).
   PubMed Web of Science ®Google Scholar
• Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J. Clin. Oncol.20(5), 1161–1163 (2002).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Vermorken JB, Van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol.8, 963–968 (1997).
   PubMed Web of Science ®Google Scholar
• Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol.16, 3345–3352 (1998).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol.19, 3312–3322 (2001).
   PubMed Web of Science ®Google Scholar
• Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol.21, 2460–2465 (2003).
   PubMed Web of Science ®Google Scholar
• Berek JS, Taylor PT, Gordon A et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol.22, 3507–3516 (2004).
   PubMed Web of Science ®Google Scholar
• Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat. Rev.21, 215–245 (1995).
   PubMed Web of Science ®Google Scholar
• Agus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer and ovarian cancer. Semin. Oncol.27, 53–63 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T-cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med.348, 203–213 (2003).
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T-cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med.10, 942–958 (2004).
   PubMed Web of Science ®Google Scholar
• Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. J. Clin. Oncol.21, 168S–174S (2003).
   Web of Science ®Google Scholar
• Evans HC, Perry CM. ADIS drug profile: oregovomab. Am. J. Cancer2, 125–133 (2003).
   Google Scholar
• Noujaim AA, Schultes BC, Baum RP, Madiyalakan R. Induction of CA125-specific B and T-cell responses in patients with MAb-B43.13 – evidence for antibody-mediated antigen-processing and presentation in vivo. Cancer Biother. Radiopharm.16, 187–203 (2001).
   PubMed Web of Science ®Google Scholar
• Schultes BC, Whiteside TL. Monitoring of immune responses to CA125 with an IFN-γ ELISPOT assay. J. Immunol. Methods279, 1–15 (2003).
   PubMed Web of Science ®Google Scholar
• Ehlen TG, Hoskins PJ, Miller D et al. A pilot Phase II study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int. J. Gynecol. Cancer (2005) (In Press).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Seiden M, Butler M et al. Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). Proc. Am. Soc. Clin. Oncol.23, 172 (2004) (Abstract 2536).
   Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunol.3, 611–618 (2002).
   PubMed Web of Science ®Google Scholar
• Camacho LH, Ribas A, Glaspy JA et al. Phase 1 clinical trial of antiCTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol.23, 164 (2004) (Abstract 2505).
   Google Scholar
• Jerne N. Towards a network theory of the immune system. Ann. Immunol. (Paris)125C, 373–389 (1974).
   PubMedGoogle Scholar
• Reinartz S, Kohler S, Schlebusch H et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II). Clin. Cancer Res.10, 1580–1587 (2004).
   PubMed Web of Science ®Google Scholar
• Pegram MD, Pienskowski T, Northfelt DW et al. Results of two open-label, multicenter Phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J. Natl Cancer Inst.96, 759–769 (2004).
   PubMed Web of Science ®Google Scholar
• Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized antiHER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol.21, 283–290 (2003).
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Leahy DJ, De Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell5, 317–328 (2004).
   PubMed Web of Science ®Google Scholar
• Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology17, 23–28 (2003).
   PubMedGoogle Scholar
• Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res.23, 263–272 (2001).
   PubMed Web of Science ®Google Scholar
• Takahasi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by pro-inflammatory cytokines. Cancer Immunol. Immunother.53, 543–550 (2004).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med.2, 1096–103 (1996).
   PubMed Web of Science ®Google Scholar
• Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer101, 1364–1374 (2004).
   PubMed Web of Science ®Google Scholar
• Persaud K, Tille JC, Liu M et al. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human antihuman VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. J. Cell Sci.117, 2745–2756 (2004).
   PubMed Web of Science ®Google Scholar
• Gordon LI, Witzig TE, Wiseman GA et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin’ lymphoma. Semin. Oncol.29, 87–92 (2002).
   PubMed Web of Science ®Google Scholar
• Seiden MV, Benigno BB, The Study of Monoclonal Antibody RadioimmunoTherapy Study Investigator Group. A pivotal Phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC). J. Clin. Oncol.22, 451S (2004) (Abstract 5008).
   Google Scholar
• Boghaert ER, Sridharan L, Armellino DC et al. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl γ calicheamicin dimethyl hydrazide targets Lewis Y and eliminates Lewis Y-positive human carcinoma cells and xenografts. Clin. Cancer Res.10, 4538–4549 (2004).
   PubMed Web of Science ®Google Scholar
• Alvarez RD, Huh WK, Khazaeli MB et al. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res.8, 2806–2811 (2002).
   PubMed Web of Science ®Google Scholar